|
|
|
|
|
Metaproterenol: profile and news
Breathing Easier Sep 26, 2005 FDA Advisory Committee Jul 14, 2005 FDA Committee To Decide If Azmacort, Alupent, Intal Remain " ... Jul 13, 2005 Changes in Inhaler Devices for Asthma And COPD Jun 19, 2005 Other information Indication For the treatment of Bronchospasm; Chronic bronchitis; Asthma; Emphysema Pharmacology Metaproterenol, a synthetic amine, is structurally and pharmacologically similar to isoproterenol. Metaproterenol is used exclusively as a bronchodilator. The pharmacologic effects of beta adrenergic agonist drugs, such as Metaproterenol, are at least in part attributable to stimulation through beta adrenergic receptors of intracellular adenyl cyclase, the enzyme which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic- 3',5'- adenosine monophosphate (c-AMP). Increased c-AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. Mechanism Of Action Metaproterenol is a moderately selective beta(2)-adrenergic agonist that stimulates receptors of the smooth muscle in the lungs, uterus, and vasculature supplying skeletal muscle, with minimal or no effect on alpha-adrenergic receptors. Intracellularly, the actions of metaproterenol are mediated by cAMP, the production of which is augmented by beta stimulation. The drug is believed to work by activating adenylate cyclase, the enzyme responsible for producing the cellular mediator cAMP. Drug Category Tocolytic Agents; Bronchodilator Agents; ATC:R03AC Brand Names/Synonyms Alotec; Alupent; CHEMBANK1252; Metaprel; Metaproterenol; Metaproterenol Polistirex; Metaproterenol Polistirex [Usan]; Metaproterenol Sulfate; Novasmasol; ORCIPRENALINE; Orciprenalina [Inn-Spanish]; Orciprenalinum [Inn-Latin]; Prometa Dosage Forms Inhalation Absorption 3% (oral bioavailability of 40%) Interactions -->Interactions for Metaproterenol: Other beta adrenergic aerosol bronchodilators should not be used concomitantly with Alupent® (metaproterenol sulfate USP) because they may have additive effects. Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.
|
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |